JP2023515664A - 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用 - Google Patents

修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用 Download PDF

Info

Publication number
JP2023515664A
JP2023515664A JP2022552538A JP2022552538A JP2023515664A JP 2023515664 A JP2023515664 A JP 2023515664A JP 2022552538 A JP2022552538 A JP 2022552538A JP 2022552538 A JP2022552538 A JP 2022552538A JP 2023515664 A JP2023515664 A JP 2023515664A
Authority
JP
Japan
Prior art keywords
nucleotides
sina
nucleotide sequence
nucleotide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515664A5 (enExample
Inventor
バイゲルマン，レオニード
クマール ラジワンシ，ヴィヴェク
ホスバッハ，マルクス
ケー． パンデイ，ラジェンドラ
ホン，ジン
エルテプ，ラクスマン
マルティネス モンテロ，サウル
コスタ，エヌ．ティラニ エス． デ
Original Assignee
アリゴス セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゴス セラピューティクス，インコーポレーテッド filed Critical アリゴス セラピューティクス，インコーポレーテッド
Publication of JP2023515664A publication Critical patent/JP2023515664A/ja
Publication of JP2023515664A5 publication Critical patent/JP2023515664A5/ja
Priority to JP2026030569A priority Critical patent/JP2026102645A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
JP2022552538A 2020-03-06 2021-03-05 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用 Pending JP2023515664A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026030569A JP2026102645A (ja) 2020-03-06 2026-02-27 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062986150P 2020-03-06 2020-03-06
US62/986,150 2020-03-06
US202063109196P 2020-11-03 2020-11-03
US63/109,196 2020-11-03
PCT/US2021/021199 WO2021178885A1 (en) 2020-03-06 2021-03-05 Modified short interfering nucleic acid (sina) molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026030569A Division JP2026102645A (ja) 2020-03-06 2026-02-27 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用

Publications (2)

Publication Number Publication Date
JP2023515664A true JP2023515664A (ja) 2023-04-13
JP2023515664A5 JP2023515664A5 (enExample) 2024-03-14

Family

ID=75278356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552538A Pending JP2023515664A (ja) 2020-03-06 2021-03-05 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用
JP2026030569A Pending JP2026102645A (ja) 2020-03-06 2026-02-27 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026030569A Pending JP2026102645A (ja) 2020-03-06 2026-02-27 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用

Country Status (17)

Country Link
US (4) US20220364096A1 (enExample)
EP (1) EP4121533A1 (enExample)
JP (2) JP2023515664A (enExample)
KR (1) KR20220163960A (enExample)
CN (1) CN115485384A (enExample)
AU (1) AU2021230601A1 (enExample)
BR (1) BR112022017287A2 (enExample)
CA (1) CA3170466A1 (enExample)
CL (1) CL2022002379A1 (enExample)
CO (1) CO2022014258A2 (enExample)
GE (2) GEP20257742B (enExample)
IL (1) IL296045A (enExample)
MX (1) MX2022011012A (enExample)
PE (1) PE20221578A1 (enExample)
PH (1) PH12022552163A1 (enExample)
TW (1) TW202208625A (enExample)
WO (1) WO2021178885A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002149XA (en) * 2017-09-14 2020-04-29 Janssen Biopharma Inc Galnac derivatives
JP2023515664A (ja) * 2020-03-06 2023-04-13 アリゴス セラピューティクス，インコーポレーテッド 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用
WO2022087011A1 (en) 2020-10-21 2022-04-28 Aligos Therapeutics, Inc. Bicyclic compounds
WO2022184852A1 (en) * 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
WO2022266193A1 (en) 2021-06-18 2022-12-22 Aligos Therapeutics, Inc. Bicyclic compounds
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
WO2023122317A2 (en) * 2021-12-23 2023-06-29 Aligos Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
WO2023224979A1 (en) * 2022-05-16 2023-11-23 University Of Massachusetts Optimized sirna scaffolds
EP4541804A4 (en) * 2022-06-14 2026-07-01 Rona Bioscience Ltd Cyclic phosphonate-modified nucleotide
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
EP4654973A1 (en) * 2023-01-26 2025-12-03 Aligos Therapeutics, Inc. Hepatitis b combination therapies
CN121152879A (zh) * 2023-02-14 2025-12-16 基愈治疗公司 经修饰的双链rna药剂
WO2024254091A1 (en) * 2023-06-05 2024-12-12 Empirico Inc. Treatment of fgg related diseases and disorders
WO2025032129A1 (en) 2023-08-08 2025-02-13 Syngenta Crop Protection Ag Novel aminoindane and aminotetraline compounds
CN117024485B (zh) * 2023-08-11 2026-02-13 江苏申基生物科技有限公司 一种2’-OMe腺苷的合成方法
WO2025096970A2 (en) * 2023-11-03 2025-05-08 Basecure Therapeutics Llc Modified oligonucleotides and methods of use thereof
CN122228245A (zh) 2023-11-14 2026-06-16 先正达农作物保护股份公司 新颖的羧酰胺化合物
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
CN117534717A (zh) * 2024-01-09 2024-02-09 凯莱英生命科学技术(天津)有限公司 5′-(e)-乙烯基磷酸酯的合成方法
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025201529A1 (en) * 2024-03-29 2025-10-02 Ractigen Therapeutics Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof
US20250368996A1 (en) 2024-05-14 2025-12-04 Aligos Therapeutics, Inc. Modified antisense oligonucleotides for treating hepatitis b virus
WO2025242321A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds
CN120796266A (zh) * 2024-07-08 2025-10-17 北京悦康科创医药科技股份有限公司 一种降低hbv基因表达的反义寡核苷酸及其应用
WO2026120028A1 (en) 2024-12-04 2026-06-11 Syngenta Crop Protection Ag Novel heteroaryl carboxamide compounds
WO2026119962A1 (en) 2024-12-04 2026-06-11 Syngenta Crop Protection Ag Novel phenyl carboxamide compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014527401A (ja) * 2011-06-30 2014-10-16 アローヘッド リサーチ コーポレイション Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
JP2015502931A (ja) * 2011-11-18 2015-01-29 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 修飾ＲＮＡｉ剤
WO2018185241A1 (en) * 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
JP2018536689A (ja) * 2015-12-10 2018-12-13 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法
JP2019504112A (ja) * 2015-12-07 2019-02-14 ジェンザイム・コーポレーション Ｓｅｒｐｉｎｃ１関連障害を処置するための方法および組成物
WO2019113393A1 (en) * 2017-12-06 2019-06-13 Avidity Biosciences Llc Compositions and methods of treating muscle atrophy and myotonic dystrophy
WO2019217459A1 (en) * 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002944A1 (en) * 2007-06-22 2008-12-31 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
CN102753187A (zh) * 2009-06-03 2012-10-24 戴瑟纳制药公司 肽-dicer底物试剂及其特异性抑制基因表达的方法
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
EP3109254B1 (en) * 2014-02-18 2018-04-11 Osaka University Crosslinked nucleoside and nucleotide
CN115957337A (zh) * 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
US11324820B2 (en) * 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
HRP20250277T1 (hr) * 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
WO2019217397A2 (en) * 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for improving strand biased
US20200147124A1 (en) 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
JP2023515664A (ja) * 2020-03-06 2023-04-13 アリゴス セラピューティクス，インコーポレーテッド 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014527401A (ja) * 2011-06-30 2014-10-16 アローヘッド リサーチ コーポレイション Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
JP2015502931A (ja) * 2011-11-18 2015-01-29 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 修飾ＲＮＡｉ剤
JP2019504112A (ja) * 2015-12-07 2019-02-14 ジェンザイム・コーポレーション Ｓｅｒｐｉｎｃ１関連障害を処置するための方法および組成物
JP2018536689A (ja) * 2015-12-10 2018-12-13 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法
WO2018185241A1 (en) * 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
WO2019113393A1 (en) * 2017-12-06 2019-06-13 Avidity Biosciences Llc Compositions and methods of treating muscle atrophy and myotonic dystrophy
WO2019217459A1 (en) * 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUCLEIC ACIDS RESEARCH, vol. 45, no. 6, JPN6025013423, 2017, pages 3528 - 3536, ISSN: 0005717369 *

Also Published As

Publication number Publication date
US20220364096A1 (en) 2022-11-17
US20220177888A1 (en) 2022-06-09
PE20221578A1 (es) 2022-10-06
IL296045A (en) 2022-10-01
JP2026102645A (ja) 2026-06-23
CO2022014258A2 (es) 2022-12-30
US20230365970A1 (en) 2023-11-16
WO2021178885A1 (en) 2021-09-10
CL2022002379A1 (es) 2023-07-28
EP4121533A1 (en) 2023-01-25
US12129469B2 (en) 2024-10-29
CA3170466A1 (en) 2021-09-10
PH12022552163A1 (en) 2024-01-29
MX2022011012A (es) 2022-10-07
CN115485384A (zh) 2022-12-16
US20230332153A1 (en) 2023-10-19
KR20220163960A (ko) 2022-12-12
AU2021230601A2 (en) 2022-10-20
BR112022017287A2 (pt) 2022-11-16
GEP20257742B (en) 2025-03-10
TW202208625A (zh) 2022-03-01
GEAP202416053A (en) 2024-10-10
AU2021230601A1 (en) 2022-10-06
US11549110B2 (en) 2023-01-10

Similar Documents

Publication Publication Date Title
US12129469B2 (en) Modified short interfering nucleic acid (siNA) molecules and uses thereof
US20210189392A1 (en) S-antigen transport inhibiting oligonucleotide polymers and methods
US20250011789A1 (en) Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
US12454691B2 (en) Modified short interfering nucleic acid (siNA) molecules and uses thereof
KR102533038B1 (ko) 변형된 올리고뉴클레오티드 및 사용 방법
US20250243491A1 (en) Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
JP2025535539A (ja) 修飾された短い干渉核酸（ｓｉＮＡ）分子及びその使用
WO2024182446A2 (en) Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
AU2023236560A1 (en) Modified gapmer oligomers and methods of use thereof
EA050671B1 (ru) МОЛЕКУЛЫ МОДИФИЦИРОВАННЫХ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ НУКЛЕИНОВЫХ КИСЛОТ (миНК) И ИХ ПРИМЕНЕНИЕ
OA21336A (en) Modified short interfering nucleic acid (siNA) molecules and uses thereof.
TW202604551A (zh) 用於治療ｂ型肝炎病毒之經修飾之反義寡核苷酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260408

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260714